Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Vfend® (voriconazole) is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:

  • Treatment of invasive aspergillosis.
  • Treatment of candidaemia in non-neutropenic patients.
  • Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
  • Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.
    Vfend® should be administered primarily to patients with progressive, possibly life-threatening infections.
  • Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Treatment considerations

  • Use of voriconazole, the gold-standard, recommended first-line treatment for invasive aspergillosis (IA), is supported by clinical trials and real-world evidence 1-4
  • Oral and IV voriconazole options deliver flexible treatment and prophylaxis for both adults and children5

Resources & Training

Find related information and test your knowledge with bespoke training modules

Find out more

Stock Hub

Register here to receive real time stock information and email alerts 

Access the Stock Hub


  1. Herbrecht R, et al. N Engl J Med. 2002; 346(6):408-15.
  2. Walsh TJ, et al. Clin Infect Dis. 2008; 46(30): 327-60.
  3. Herbrecht R, et al. 2013-Update of the ECIL Guidelines for Antifungal Therapy in Leukaemia and HSCT Patients (ECIL-5). Dated accessed: November 2019.
  4. Baddley JW, et al. Clin Infect Dis. 2010; 50(12): 1559-7.
  5. Vfend ® Summary of Product Characteristics.